Patents Issued in July 14, 2020
-
Patent number: 10709667Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: GrantFiled: May 3, 2019Date of Patent: July 14, 2020Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Daniel G. Anderson, Robert S. Langer, Tram T. Dang
-
Patent number: 10709668Abstract: The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an active ingredient and a diluent.Type: GrantFiled: May 4, 2016Date of Patent: July 14, 2020Assignee: CONFLUENCE PHARMACEUTICALS, LLCInventors: Steven L. Johns, Kenneth G. Payie, Badrinath R. Doniparthi, Shivaraj B. Munianjanappa
-
Patent number: 10709669Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.Type: GrantFiled: October 15, 2019Date of Patent: July 14, 2020Assignee: LTS LOHMANN Therape-Systeme AGInventor: Walter Müller
-
Patent number: 10709670Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.Type: GrantFiled: May 22, 2018Date of Patent: July 14, 2020Assignee: GBS GLOBAL BIOPHARMA, INC.Inventors: Andrea Small-Howard, Helen Turner
-
Patent number: 10709671Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.Type: GrantFiled: June 16, 2016Date of Patent: July 14, 2020Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 10709672Abstract: An object of the present invention is to provide a polyphenol-containing solid composition that enables efficient ingestion of a polyphenol. This object can be achieved by a solid composition containing (1) an amorphous poorly water-soluble polyphenol, (2) a hydrophilic polymer, and (3) at least one nonionic surfactant selected from the group consisting of polyglycerol fatty acid esters, sucrose fatty acid esters, and lecithins.Type: GrantFiled: October 7, 2016Date of Patent: July 14, 2020Assignee: SAN-EI GEN F.F.I., INC.Inventors: Tomohiro Nakao, Mikihiko Nakamura, Masayuki Nishino
-
Patent number: 10709673Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: September 13, 2019Date of Patent: July 14, 2020Assignee: GW Research LimitedInventor: Geoffrey Guy
-
Patent number: 10709674Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: November 8, 2019Date of Patent: July 14, 2020Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 10709675Abstract: A nutraceutical composition comprising fullerene (e.g., C60), curcumin, and at least one of black seed oil and moringa oil. Preferably, the nutraceutical composition is substantially free of particles having a size greater than 0.2 ?m. The nutraceutical composition can be used to prevent and to treat eye conditions (e.g., cataract) by local administration to the eye, oral administration, or both.Type: GrantFiled: October 1, 2019Date of Patent: July 14, 2020Inventor: Max C. Champie
-
Patent number: 10709676Abstract: Provided are applications of spermine and derivatives thereof. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds capable of effectively interfering with PAICS activity, reducing SAICAR synthesis, and ultimately reducing SAICAR accumulation, in order to achieve the goal of treating or reducing ADSL deficiency. A better effect in the treatment or improvement of ADSL deficiency is expected from the joint use of at least two of the described compounds.Type: GrantFiled: September 8, 2017Date of Patent: July 14, 2020Assignee: Geneheal Biotechnology Co., Ltd.Inventors: Wuguang Pan, Wei Zhu
-
Patent number: 10709677Abstract: The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.Type: GrantFiled: July 2, 2015Date of Patent: July 14, 2020Assignee: INFLECTIS BIOSCIENCEInventor: Philippe Guedat
-
Patent number: 10709678Abstract: Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease, having a recurrent cardiovascular event or reducing the severity of a secondary cardiovascular event, wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.Type: GrantFiled: June 29, 2018Date of Patent: July 14, 2020Assignee: NeuroBo Pharmaceuticals, Inc.Inventor: Charles L. Bisgaier
-
Patent number: 10709679Abstract: A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 50 mg to 425 mg per oral combination drug formulation.Type: GrantFiled: November 26, 2019Date of Patent: July 14, 2020Assignee: ARSTAT, INC.Inventor: Arkady Rubin
-
Patent number: 10709680Abstract: This invention relates to methods for improving the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: GrantFiled: March 2, 2018Date of Patent: July 14, 2020Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Patent number: 10709681Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: January 27, 2017Date of Patent: July 14, 2020Assignee: UNIVERSITY OF MISSISSIPPIInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Patent number: 10709682Abstract: The present invention relates to the treatment or prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical compositions comprising such an NKCC1 chloride co-transporter modulator as an active agent, a method for the treatment or prevention of tinnitus by administering such a chloride co-transporter modulator, and a screening method for the identification and characterization of compounds capable of modulating chloride co-transporter NKCC1.Type: GrantFiled: January 12, 2018Date of Patent: July 14, 2020Assignee: Otolanum AGInventors: Marlies Knipper-Breer, Luckas Ruettiger
-
Patent number: 10709683Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.Type: GrantFiled: January 2, 2019Date of Patent: July 14, 2020Inventors: Claudius Weiler, Thomas Duch, Marbod Haase, Timothy Shane Priddy, Heike Stettler
-
Patent number: 10709684Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 25, 2019Date of Patent: July 14, 2020Assignees: Merck Sharp & Dohme Corp., Pfizer Inc.Inventors: Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
-
Patent number: 10709685Abstract: Disclosed are methods of treating anxiety or depression, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP), 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 31, 2016Date of Patent: July 14, 2020Assignee: Georgetown UniversityInventors: Kenneth J. Kellar, Yingxian Xiao, Patrick A. Forcelli
-
Patent number: 10709686Abstract: The present invention is related to a method of treating idiopathic pulmonary fibrosis comprising administering to a subject in need thereof an effective amount of a composition containing a compound that binds FK506 binding protein 4.Type: GrantFiled: March 20, 2019Date of Patent: July 14, 2020Assignee: DAVID WEINSTEIN CONSULTING, INC.Inventor: David Weinstein
-
Patent number: 10709687Abstract: The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of: (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity, (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, and (iii) establishing a daily dosage range per human adult per day wherein (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.Type: GrantFiled: June 8, 2017Date of Patent: July 14, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, BIODOL THERAPEUTICSInventor: Jean Valmier
-
Patent number: 10709688Abstract: This invention provides a pharmaceutical composition for treating or preventing synucleinopathy comprising a compound represented by formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 31, 2017Date of Patent: July 14, 2020Assignees: Tohoku University, National University Corporation Okayama UniversityInventors: Kohji Fukunaga, Hiroyuki Miyachi, Hiroaki Ishida, Shintaro Ban
-
Patent number: 10709689Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.Type: GrantFiled: May 28, 2014Date of Patent: July 14, 2020Assignee: SLA PHARMA AGInventor: David Nigel Armstrong
-
Patent number: 10709690Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.Type: GrantFiled: May 29, 2018Date of Patent: July 14, 2020Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventor: Tianxin Yang
-
Patent number: 10709691Abstract: The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.Type: GrantFiled: October 30, 2018Date of Patent: July 14, 2020Assignee: RECORDATI AGInventors: Stefania Beato, Peggy Quinton
-
Patent number: 10709692Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.Type: GrantFiled: December 2, 2016Date of Patent: July 14, 2020Assignee: Denali Therapeutics Inc.Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
-
Patent number: 10709693Abstract: A method for increasing the number of CD4+ T-lymphocytes in the serum of a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an amount of an L-isomer of ?-lactam effective to increase the number of CD4+ T-lymphocytes in said patient's serum.Type: GrantFiled: August 19, 2019Date of Patent: July 14, 2020Assignee: Alpha-1 Biologics, LLCInventors: Cynthia L. Bristow, Ronald H. Winston
-
Patent number: 10709694Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.Type: GrantFiled: May 16, 2019Date of Patent: July 14, 2020Assignee: Salix Pharmaceuticals, Inc.Inventor: William Forbes
-
Patent number: 10709695Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: April 5, 2019Date of Patent: July 14, 2020Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Michael P. Demartino, Huiping Amy Guan
-
Patent number: 10709696Abstract: A method for treating autoimmune diseases or a disease associated with chronic inflammation can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an Arid5a inhibitor and a pharmaceutically acceptable carrier. The Arid5a inhibitor can have the formula or a pharmaceutically acceptable salt thereof. The disease associate with chronic inflammation can be multiple sclerosis. A screening method can include identifying candidate Arid5a inhibitors through in silico predicted binding to Arid5a target domains and confirming Arid5a inhibition through in vitro binding assays.Type: GrantFiled: December 17, 2019Date of Patent: July 14, 2020Assignee: King Faisal UniversityInventor: Hamza Naim Ahmad Hanieh
-
Patent number: 10709697Abstract: This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula (I), salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.Type: GrantFiled: July 13, 2016Date of Patent: July 14, 2020Assignees: Emory University, Georgia State University Research Foundation, Inc.Inventors: Hyunsuk Shim, Suazette Reid Mooring, Renren Bai
-
Patent number: 10709699Abstract: Provided are a pyridone derivative pharmaceutical composition and a preparation method thereof. In particular, provided are a pharmaceutical composition containing a pyridone derivative or a pharmaceutically acceptable salt thereof and the preparation method thereof. The pharmaceutical composition contains an active ingredient 2-((2-fluoro-4-iodophenyl)amino)-1-methyl-4-((6-methylpyridin-3-yl)oxy)-6-oxo-1,6-di hydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof, and hydroxypropyl methylcellulose, and the pharmaceutical composition has good dissolution.Type: GrantFiled: November 24, 2017Date of Patent: July 14, 2020Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Huan Ding, Daimei Zhang
-
Patent number: 10709700Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.Type: GrantFiled: September 15, 2015Date of Patent: July 14, 2020Assignee: Orphazyme A/SInventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
-
Patent number: 10709701Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-HLA-DR antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The methods and compositions are particularly useful for treating AML, ALL or multiple myeloma.Type: GrantFiled: November 30, 2018Date of Patent: July 14, 2020Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg
-
Patent number: 10709702Abstract: Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.Type: GrantFiled: October 7, 2016Date of Patent: July 14, 2020Assignee: AMD THERAPEUTICS LLCInventor: Hiroaki Serizawa
-
Patent number: 10709703Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.Type: GrantFiled: November 21, 2019Date of Patent: July 14, 2020Assignee: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
-
Patent number: 10709704Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.Type: GrantFiled: May 6, 2016Date of Patent: July 14, 2020Assignee: Georgetown UniversityInventor: Charbel Moussa
-
Patent number: 10709705Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.Type: GrantFiled: August 28, 2017Date of Patent: July 14, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Jianyong Chen
-
Patent number: 10709706Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: December 30, 2016Date of Patent: July 14, 2020Assignee: Karopharm Therapeutics Inc.Inventor: Erkan Baloglu
-
Patent number: 10709707Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.Type: GrantFiled: April 6, 2017Date of Patent: July 14, 2020Assignee: Oyster Point Pharma, Inc.Inventors: Douglas Michael Ackermann, James Loudin, Kenneth J. Mandell
-
Patent number: 10709708Abstract: The invention provides combinations comprising a MERTK inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor and methods of use thereof, including methods of treating disorders such as cancer.Type: GrantFiled: March 17, 2017Date of Patent: July 14, 2020Assignees: The University of North Carolina at Chapel Hill, Emory UniversityInventors: Dan Yan, H. Shelton Earp, III, Deborah Ann DeRyckere, Douglas Kim Graham, Jing Wan
-
Patent number: 10709709Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.Type: GrantFiled: December 18, 2018Date of Patent: July 14, 2020Assignee: Pfizer Inc.Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
-
Patent number: 10709710Abstract: The present invention refers to a composition comprising uric acid for its use in the treatment of brain stroke in a patient treated by means of mechanical thrombectomy.Type: GrantFiled: May 9, 2017Date of Patent: July 14, 2020Assignees: HOSPITAL CLINIC DE BARCELONA, INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUSTI PI I SUNYER (IDIBAPS)Inventor: Angel Chamorro Sanchez
-
Patent number: 10709711Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.Type: GrantFiled: December 20, 2018Date of Patent: July 14, 2020Assignee: G1 Therapeutics, Inc.Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
-
Patent number: 10709712Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: February 12, 2019Date of Patent: July 14, 2020Assignee: NOVARTIS AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
-
Patent number: 10709713Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.Type: GrantFiled: August 25, 2019Date of Patent: July 14, 2020Assignee: BAUDAX BIO, INC.Inventors: Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
-
Patent number: 10709714Abstract: The provided embodiments are based in some aspects on the demonstration herein of a role for gastrin in regulating the aging gut-ovary axis and effects of targeting gastrin activity in reversing gastrin-mediated bone loss. Provided are methods, compositions and agents, including gastrin antagonists, for treatment, amelioration, and prevention of bone diseases and conditions. Methods for treating a bone disease or condition associated with hypergastrinemia in a subject in need thereof may comprise administering to the subject at least one dose of a therapeutically effective amount of a gastrin receptor-targeting agent, thereby treating the bone disease or condition associated with hypergastrinemia.Type: GrantFiled: November 21, 2014Date of Patent: July 14, 2020Assignee: Clifton Life Sciences LLCInventors: Irvin Mark Modlin, Mark Kidd
-
Patent number: 10709715Abstract: Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.Type: GrantFiled: December 3, 2018Date of Patent: July 14, 2020Assignee: Cipla LimitedInventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
-
Patent number: 10709716Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.Type: GrantFiled: March 28, 2019Date of Patent: July 14, 2020Assignee: Lipocine Inc.Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
-
Patent number: 10709717Abstract: There is provided a polymer comprising: (i) a repeat unit derived from a compound of formula (I) (Formula (I)) wherein, R1 and R2 are each independently selected from OH, OR?, SH, SR?, NH2, NHR? and NR?2; R? is C1-20 hydrocarbyl; each n is independently 0 or an integer between 1 and 6; each m is independently 0 or an integer between 1 and 4, and preferably at least one m is 1; and q is an integer between 1 and 8; and; (ii) a biologically active molecule, wherein said biologically active molecule is covalently bonded to said repeat unit; as well as methods for preparing such polymers, particles comprising said polymers and uses of said polymers and particles including use in the treatment of disease.Type: GrantFiled: October 13, 2015Date of Patent: July 14, 2020Assignee: SPIREA LIMITEDInventors: Myriam Marie Ouberai, Mark Welland